Transcript Highlights:

• I am, uh, first a, uh, FDA regulatory consultant, so I have filed hundreds of PMTAs.
• going to ask Chairman Leach, I just read in here, which is why China, the vape products have to be FDA
• approved, and there are no FDA approved products coming out of China.
• Um, and with some of those discussions, but they require FDA approval, and there are zero FDA approved

Transcript Highlights:

• Despite FDA approval for over-the-counter, or OTC, use, Medi-Cal still requires a prescription for Opill
• They are FDA-approved, 98% effective with adherence.
• They are FDA approved, 98% effective with adherence, safe even in patients with hypertension and smoking
• I was thrilled when the FDA approved the first over-the-counter contraceptive pill, Opill.
• I was thrilled when the FDA approved the first over-the-counter contraceptive pill opal.

Summary: The Assembly Business and Professions Committee held its first regular bill hearing of 2025 and considered a wide range of measures on health care access, professional regulation, animal welfare, and consumer protection. Early in the hearing, the committee adopted its rules and then approved a consent calendar of several bills, including measures by Chen, Caloza, Carrillo, Arreguín, Berman, and Flora. The committee also took up AB 1082, which would allow California nursing students enrolled in out-of-state programs to complete clinical training in California; supporters said it would help address the nursing shortage and keep students closer to home, while opponents warned it could worsen already limited clinical placement capacity and reduce oversight. The bill passed on a do pass recommendation to Appropriations after a quorum was established. The committee then heard and advanced several health-related bills. AB 50, by Assembly Member Bonta, would ease Medi-Cal access to over-the-counter hormonal contraception by removing the need for a prescription for coverage purposes; pharmacists, reproductive health advocates, and medical groups supported the bill, and it passed unanimously to the Committee on Health. AB 489, also by Bonta, would prohibit AI systems from misrepresenting themselves as licensed health professionals; supporters from medical, psychiatric, behavioral health, and other professional groups said the bill would protect patients from misleading chatbot advice, and it passed to Privacy and Consumer Protection. AB 481, by Assembly Member Rubio, would expand the tasks that federally qualified lab personnel can perform under CLIA supervision to help address lab staffing shortages; labor groups raised concerns about training, certification, and supervision, but the bill passed to Appropriations with an amended do pass recommendation. The committee also considered animal welfare and access-to-care measures. AB 631, by Assembly Member Lee, would require animal shelters to post intake and outcome data online; supporters said the reporting would improve policy and resource allocation, while members discussed how the requirement would work for shelters without websites, and the bill passed to Appropriations. AB 867, also by Lee, would prohibit cat declawing except when medically necessary for the animal; animal welfare groups strongly supported the bill, while the veterinary association opposed it as an improper legislative regulation of veterinary surgery, and the bill passed to Appropriations. Finally, AB 1307 would create a pilot program allowing a limited number of qualified dentists trained in Mexico to practice in underserved California areas; supporters framed it as a cost-neutral way to address major dental access gaps, the California Dental Association remained opposed unless amended, and the bill passed to Appropriations. Several members later added their votes on the various items after the hearing, and the committee kept the hearing open briefly to allow additional add-ons.

Transcript Highlights:

• allows a physician to perform stem cell therapy or birth tissue therapy that is not approved by the FDA
• The therapy that is not approved by the FDA is allowed if it is within the physician's lawful scope of
• The bill requires a physician advertising stem cell or birth tissue therapies not approved by the FDA
• I have lobbied at the highest levels with the FDA. The stance on these.
• I have lobbied at the highest levels with the FDA. There is a lot of medical dogma.

Bills: SB1014, SB1094, SB1146, SB1177, SB1192, SB1194, SB1214, SB1372, SB1390, SB1398, SB1399, SB1494, SB1557, SB1561, SB1564, SB1602, SB1603, SB1621, SB1628, SB1629, SB1713, SB1752, SB1776, SB1813, SB1814, SB1821

Keywords: gender transition, gender detransition, health insurance, medical procedures, insurance claims, official documents, Arizona law, gender reassignment, civil liability, minors, medical consent, detransition, dependent children, foster care, periodic review, court hearings, child welfare, public funds, prohibition, Arizona legislation

Summary: The committee heard and acted on several health-related bills, with the longest discussion centered on SB 1214, the Arizona Stem Cell Therapy Act. The bill would regulate stem cell and birth tissue therapies, bar use of tissues derived from aborted fetuses or embryos, require informed consent and disclosure for non-FDA-approved therapies, and create civil and criminal penalties for violations. Supporters framed it as a patient-safety and bioscience-innovation measure, while opponents objected to the abortion-related language and felony penalties. The committee approved SB 1214 on a 4-3 vote. The committee also advanced SB 1194, which would prohibit health professionals and institutions from denying care or reducing care quality based on vaccination status, and SB 1814, which creates a study committee on substance use disorder treatment standards and oversight. SB 1602, increasing monthly stipends for kinship foster care parents, and SB 1603, expanding child-only cash assistance eligibility for certain foster and relative placements, were both amended and passed unanimously. SB 1177, barring public funds from being used for gender transition procedures, and SB 1014, requiring insurance coverage for detransition care and related reporting, both drew strong support and opposition and were each approved on 4-3 votes. Later, the committee unanimously passed SB 1628, requiring insurers and health plans to report claims-denial and prior-authorization data to DIFI for public reporting, and SB 1629, requiring AHCCCS managed care organizations to give advance notice and network-adequacy documentation before terminating high-volume providers without cause. Supporters of both bills emphasized transparency and patient access, while opponents argued the measures duplicated existing federal or state oversight. The committee then heard SB 1752, which would criminalize commercial harvesting or sale of mescaline while preserving a religious-use defense; the sponsor said it was intended to address improper sales of peyote-derived substances, but no final action on that bill was taken in the portion provided.

Transcript Highlights:

• Came out in the 1980s, indications that are FDA-approved for use for management of hypertension.
• On that, but that is an FDA-approved indication for the use of Mifepristone.
• In 2016, the FDA removed the requirement of reporting any non-fatal complications.
• They are more dangerous than what the FDA has reported.
• They are not FDA regulated.

Bills: SB10, SB16, SB6, SB 6, SB 10, SB 16

Keywords: trafficking, prostitution, affirmative defense, victims, criminal justice reform, victim rights, criminal justice, judicial reform, court procedures, mental health services, criminal penalties, court security, SB 6, Woman and Child Protection Act, abortion, abortion-inducing drugs, medication abortion, mifepristone, misoprostol, pro-life

Transcript Highlights:

• The FDA approved...
• The FDA approved adapalene, which is a form of a retinoid that's over the counter, in 1996, which is
• see that there's, you know, a lactic acid wash or a glycolycolic acid wash or a dappling, which is FDA
• And whether or not the FDA industry has tested this clinically in a lab setting, they have done that
• Look, at the end of the day, there are no FDA studies right now.

Summary: The committee heard a series of environmental safety and toxic materials measures, with several bills moving forward on unanimous or near-unanimous votes to Appropriations. Early in the meeting, the consent calendar was approved, including AB 372, AB 455, AB 1096, AB 1102, and AB 754. AB 362 by Assembly Member Ramos, which would recognize tribal beneficial uses of water and strengthen consultation and protection for tribal water uses, drew strong support from tribes and environmental groups. Water agencies and local government representatives opposed unless amended, raising concerns about CEQA requirements, co-management language, and conflicts with existing water law. The bill advanced to Appropriations, with some members voting aye and others not voting or absent. AB 728 by Assembly Member Lee would require age verification for the sale of certain anti-aging skin care products to minors. The author and a youth witness described social media-driven use of adult skin products by children and alleged skin damage, while supporters argued age checks are a reasonable consumer protection. Dermatologists and retailers opposed the bill, saying it could restrict legitimate acne and other medical uses of over-the-counter products, create compliance problems, and lacked a clear scientific basis. The committee discussed possible ambiguity in the bill’s definition of anti-aging products, but the measure still passed to Appropriations. AB 532 on low-income water rate assistance, AB 773 on copper-based anti-fouling paint, AB 998 on household hazardous waste disposal of vape pens, AB 1031 on geothermal hazardous waste fees, and AB 864 on solar panel hazardous waste and recycling all received strong support and advanced to Appropriations. Supporters for AB 532 emphasized water affordability and local program authority; AB 773 supporters said conflicting state water and pesticide rules are creating confusion for harbors and cities; AB 998 was presented as a practical way to let schools and local facilities dispose of confiscated vape devices safely; AB 1031 was framed as reducing DTSC fee burdens on geothermal development in Imperial County; and AB 864 would ease recycling and reuse of end-of-life solar panels. The committee also began hearing AB 1264 on ultra-processed foods in school meals, with the author and supporters arguing it would phase out the most harmful ultra-processed foods from school meals by 2032, but the transcript cuts off before the full discussion and any action on that bill.

Transcript Highlights:

• The FDA currently regulates and approves menstrual products for the market as medical devices for safety
• In January of this year, the FDA conducted an independent review which concluded that there are no safety
• concerns associated with tampon use. and contaminant exposure, the FDA continues to recommend FDA clear

Keywords: 988, house, all

Transcript Highlights:

• These products are not FDA approved and have raised alarms due to an increase in poison control calls
• actively working to promote policies like SB 1094 to drive down spending while expanding access to FDA-approved
• It aligns California with FDA clinical evolution and Medicare policy, allowing for the automatic substitution
• SB 1094 allows pharmacists to substitute FDA-approved biosimilars unless... ...unless the prescriber
• Health Advantage last year, we transitioned our entire book of business for patients using Stelara to an FDA-approved

Summary: The committee heard several bills, beginning with SB 1312 by Senator Richardson on abandoned endowed-care cemeteries. Richardson described vandalism, theft, and neglect at abandoned cemeteries and said the bill would define abandonment, create a process for local governments to declare a cemetery abandoned, and allow the Bureau to act as conservator of endowment funds. Support came from Marin County, while county and special district groups opposed or had concerns, arguing the bill could shift burdens to local governments or public cemetery districts without enough safeguards. Members expressed general support but noted the need for further work; the bill was discussed but no final vote was taken in the excerpt. The committee then took up SB 758 by Senator Umberg, which would restrict retail sales of nitrous oxide to curb misuse. Supporters, including the League of California Cities, narcotic officers, counties, pediatricians, and other local governments and health groups, said easy access at smoke shops and convenience stores has fueled recreational abuse and health harms. There was no opposition testimony, and members voiced strong support for a statewide approach over city-by-city bans. The bill was well received, with the author closing in support. Dr. Weber-Pierson presented SB 1094, a health care affordability bill on biosimilars and biologic substitution. The bill would allow pharmacists to substitute biosimilars under certain conditions, require advance notice to providers and patients, and add reporting on savings; the author said amendments would strengthen provider notice and preserve the ability to mark prescriptions “do not substitute.” Supporters from health plans, insurers, pharmacies, labor, business, and some provider groups argued the bill would lower costs and expand access. Opponents, including dermatology and rheumatology groups and biotech interests, warned about non-medical switching, prior authorization delays, and patient harm. After extensive discussion, the committee voted 13-0 to pass SB 1094 to the Committee on Health. The committee also passed SB 849 by Dr. Weber-Pierson, which would bar reinstatement of physicians who surrendered their licenses while a sexual misconduct accusation was pending. The Medical Board and California Medical Association were generally supportive or neutral, and members praised the bill’s patient-protection focus. SB 993 by Senator Ochoa Bogh, which limits routine disclosure of identifying information for mental health professionals in correctional and psychiatric settings while preserving complaint processes, also passed unanimously to Appropriations. SB 1002 by Senator Niello, extending the David Hall Act to allow certain patients in remission to continue telehealth care with out-of-state specialists, drew strong patient support but opposition from the Medical Board and CMA over licensure and oversight concerns; the committee voted it out on a split roll with some members not voting. Finally, SB 1263 by Senator McGuire, aimed at protecting wildfire survivors and workers by requiring licensed, trained contractors for post-disaster residential debris removal, received support from labor and the Contractors State License Board, with contractors raising a narrower amendment concern about scope.

Transcript Highlights:

• Those are currently legal today through the FDA. I think one thing you need to understand.
• So to be clear, CBD and CBG are generally recognized as safe, or GRAS, as designated by the FDA.
• Epidiolex is an FDA-approved CBD prescription. If a person under 21 needs CBD, they can.
• They advise THC products as medicine despite lacking FDA approval.
• The FDA specifically prohibits interstate commerce of consumable products manufactured.

Bills: SB5, SB11, SB12, SB 5, SB 11, SB 12

Keywords: hemp regulation, consumable products, cannabinoids, occupational licenses, criminal offenses, SB 11, Texas attorney general, election crimes, election law enforcement, criminal prosecution, Election Code, Government Code Chapter 402, local prosecutors, county attorney, district attorney, grand jury, probable cause reports, state election offenses, voter fraud, election integrity

Transcript Highlights:

• Ivermectin is generally well-tolerated when used at FDA-approved doses for approved indications."
• And then, so on the one hand, you're saying the FDA and the CDC are pushing vaccines, but your bill also
• Your bill also talks, with little to no evidence, that ivermectin is safe and effective, that the FDA
• dealing with COVID-19, as well as vaccinations, I've never seen ivermectin approved on any level by the FDA
• And again, if it is taken at FDA-approved dosage levels, as our analysis points out, then it's not proven

Summary: The committee first took up CS for SB 896 on school safety, which would expand the Guardian program to public postsecondary institutions, require active assailant response plans and threat management protocols, improve reporting and information sharing, and make it a felony to discharge a weapon within 1,000 feet of a campus. A late-file amendment by Senator Polsky was adopted to clarify that students who are also employees or faculty at a public postsecondary institution are not eligible for the Guardian program. The bill drew strong opposition from faculty, students, and gun-safety advocates who argued that more guns on campus would create confusion, weaken safety, and undermine campus police; supporters said trained guardians would improve deterrence and protection. After debate, the committee reported the bill favorably by a roll call vote. The committee then considered SB 1690 on child care and early learning services, which updates child care laws, reduces some regulatory burdens, and expands the Florida Education Foundation’s authority to fundraise for early learning from birth through VPK. Members discussed oversight of the related direct-support organization and the removal of certain notice requirements, while supporters from Moms Rising and other advocates said the bill would help families access affordable, high-quality child care and support home-based providers. One opponent argued the bill added more government regulation, but the committee adopted the amendment and reported the bill favorably. Next, the committee passed CS for SB 118, a narrow bill on non-ad valorem special assessments for recreational vehicle parks, clarifying how assessments are calculated for RV spaces and campsites. The bill received supportive comments from RV advocates and was reported favorably without controversy. The committee then took up CS for SB 1220, the Department of Transportation package, which included provisions on seaports and airports, personal delivery devices, autonomous vehicles, broadband and utility permitting, and advanced air mobility. Amendments were adopted that revised research institute membership, limited some delivery-device provisions, and clarified cruiser light rules for law enforcement; after questions about utility preemption and PDD safety, the bill was reported favorably. Finally, the committee began hearing SB 1756 on medical freedom, which would require new vaccine educational materials, expand school-entry exemptions to include conscience-based objections, limit the Surgeon General’s emergency vaccination authority, and allow behind-the-counter ivermectin for adults with written information and liability protections. The bill drew extensive testimony from both supporters and opponents, with supporters emphasizing parental rights, informed consent, and vaccine injury concerns, and opponents warning about reduced immunization rates, public health risks, and the appropriateness of ivermectin provisions. The transcript ends during public testimony and debate on SB 1756, before final action on that bill is shown.

Transcript Highlights:

• This bill is premised on the belief, it seems, that there's a concern that the FDA and the CDC are recklessly
• And then, so on the one hand, you're saying the FDA and the CDC are pushing vaccines, but your bill also
• Your bill also talks, with little to no evidence, that ivermectin is safe and effective, that the FDA
• dealing with COVID-19, as well as vaccinations, I've never seen ivermectin approved on any level by the FDA
• And again, if it is taken at FDA-approved dosage levels, as our analysis points out, then it's not proven

Bills: S0118, S0896, S1690, S1756

Keywords: recreational vehicle parks, special assessments, property tax, occupancy rates, commercial assessment, school safety, guardian program, firearms, crimes near schools, security assessments, public postsecondary education, medical freedom, vaccination, ivermectin, healthcare practitioner liability, immunization exemptions

Summary: The committee first took up CS for SB 896, a school safety bill expanding the Guardian program to public postsecondary institutions. The bill requires active assailant response plans, security risk assessments, threat-management protocols, use of the suspicious activity reporting tool, and allows voluntary participation in Guardian for colleges and universities. A late-file amendment by Senator Polsky was adopted to clarify that students who are also employees or faculty are not eligible for Guardian. Members debated campus carry concerns, storage of firearms, and whether the bill could lead to broader gun access on campuses. Several faculty and gun-safety advocates testified against the bill, while supporters argued trained guardians can deter violence. The committee reported the bill favorably by roll call vote. The committee then approved CS for CS for CS for SB 1690 on child care and early learning services. The bill updates child care laws, clarifies regulations, and reduces overregulation of before- and after-school programs. An amendment expanded authority for the Florida Education Foundation to fundraise for early learning from birth to VPK. Testimony was largely supportive, emphasizing affordability, access to quality child care, and relief for working families, though one speaker opposed the bill as an expansion of government. The bill was reported favorably. Next, the committee passed CS for CS for SB 118, which clarifies how non-ad valorem special assessments are applied to recreational vehicle parks and limits the square footage used for assessment purposes to the maximum size of an RV space. The committee also approved CS for CS for SB 1220, the Department of Transportation package, which addresses seaport and airport planning, personal delivery devices, autonomous vehicles, advanced air mobility, toll programming, and other transportation-related changes. Amendments modified provisions on personal delivery devices, utility permits, autonomous vehicle penalties, and law-enforcement cruiser lights. Both bills were reported favorably. Finally, the committee began hearing SB 1756, the medical freedom bill, which proposes new vaccine information requirements, conscience-based school immunization exemptions, limits on compelled vaccination during public health emergencies, and behind-the-counter access to ivermectin for adults. The sponsor and supporters framed the bill as strengthening informed consent and parental rights, while opponents and some senators raised concerns about vaccine hesitancy, herd immunity, and the inclusion of ivermectin. Public testimony was extensive and sharply divided. The transcript ends during continued testimony and debate on SB 1756, before a final vote is taken.

Transcript Highlights:

• The FDA tar in your body as well. The FDA tar in your body as well.
• It is approved approved by by the FDA? It is approved by the FDA. How long has it been by the FDA.
• I know that the FDA has done many studies on it. the FDA has done many studies on it. the FDA has done
• Well, FDA has uh reviewed correct? Well, FDA has uh reviewed correct?
• FDA conclusion was that it something. FDA conclusion was that it something.

Bills: SB 1, HB 500, SB 1, HB 1400, HB 1094, HB 365, HB 1109, HB 647, HB 500

Keywords: appropriations, budget, state funding, education, healthcare, infrastructure, state budget, mental health funding, education funding, infrastructure improvements, public safety, groundwater, water conservation, financial assistance, Texas Water Development Board, innovation fund, local conservation districts, transportation protection agreement, funeral services, insurance exemption

Transcript Highlights:

• There was a recent note from the FDA; this is the FDA. They reviewed the data.
• But if you do have doubts about that study, the FDA claims its serious adverse effects... ...happened
• And this FDA number is also from before the pills were available in the form and the like. ...that they
• Bills aren't even FDA-regulated, being shipped from out of the country with little to no direction.
• We were there to answer her questions, review FDA guidelines, and connect her with vital support and

Bills: HB7, SB 8, HB7, SB 8

Keywords: abortion, healthcare, jurisdiction, civil action, qui tam, prohibition, state law, sex designation, restroom access, civil penalties, private civil right of action, women's privacy, 997, house, all

Transcript Highlights:

• for non-FDA approved drugs. for non-FDA approved drugs.
• And three, require preapproval for non-FDA-approved drugs as stated in their testimony.
• And three, require preapproval for non-FDA-approved drugs as stated in their testimony.
• And three, require preapproval for non-FDA-approved drugs as stated in their testimony.
• And three, require preapproval for non-FDA-approved drugs as stated in their testimony.

Keywords: 912, senate, all

Summary: The joint HHS and LBT meeting opened with accessibility concerns, as several blind attendees arrived after the general public had already been seated. The chair apologized and said future hearings would try to seat blind members earlier. The committee also announced the hearing was being streamed on YouTube, testimony would be limited to one minute, and written testimony was available online. The first bill heard was SB 2281, relating to the use of artificial intelligence in healthcare. The Department of Health supported transparency for patients but preferred disclosure through provider websites and office signage rather than a new regulatory program. The Hawaii Medical Association and Healthcare Association of Hawaii generally supported the bill’s intent but raised concerns about administrative burden and suggested a working group or model policies. Hawaii Pacific Health said it already uses AI for note-taking and patient portal functions and worried that written notice requirements could create too much consumer information. In response, the chair emphasized that patients should be informed when AI is used, especially if it affects diagnosis or consequential decisions, and said AI should not be making medical decisions. The committee later voted to recommend SB 2281 pass with amendments, including narrowing the definition of consequential decisions, removing certain language requested by DOH, adding a two-year implementation period, and setting a far-future defective date for further discussion; both committees adopted the recommendation, with the chair voting aye and the vice chair voting with reservations. The second major bill was SB 2852, a civil rights measure focused on digital access for people with disabilities. The Hawaii State Council on Developmental Disabilities, Hawaii Civil Rights Commission, Hawaii Disability Rights Center, and the National Federation of the Blind of Hawaii all supported the bill, arguing that existing law clearly protects physical access but should also make digital access explicit. Blind testifiers described how accessible technology, such as VoiceOver on iPhones, allows them to participate independently in public processes and warned that inaccessible digital systems can create barriers for thousands of blind residents. One testifier, an attorney with disability-law experience, supported the bill’s intent but said the draft had flaws, including no exceptions for archived materials, no distinction between small and large businesses, and concerns about the timing and choice of accessibility standards; he suggested delegating regulatory authority to the Hawaii Civil Rights Commission. The bill’s sponsor said he supported DAB’s proposed amendments, and the committee indicated those amendments would address many of the concerns raised. No final vote on SB 2852 was taken in the portion provided. The committee then took up SB 2751, which defines compounded prescription drugs for workers’ compensation purposes. The Department of Labor and Industrial Relations supported the bill but requested clarifying amendments to keep pharmacists as the primary professionals authorized to compound in licensed pharmacies and to limit any physician compounding authority to the physician’s own patient. Supporters included the Work Injury Medical Association of Hawaii, while Solera Integrated Medical Solutions opposed the measure, arguing the current definition was already broad enough and warning about cost inflation, especially with 503B bulk compounding facilities and physician dispensing. In questioning, members asked about rural access, reimbursement for 503B products, and late testimony suggesting definitions for 503A and 503B facilities, limits on physician dispensing to 30 days post-injury, and pre-approval for non-FDA-approved drugs. DLIR said not every rural community has licensed pharmacists available, that products with a national drug code are reimbursed at 140%, and that 503B facilities raise concerns because they are bulk manufacturers rather than patient-specific compounding operations. The meeting then moved into decision-making on SB 2281; the chair’s pass-with-amendments recommendation was adopted by both committees, with the vice chair voting with reservations.

Transcript Highlights:

• What about FDA?
• You mentioned FDA. Is that related to the ivermectin piece?
• Ivermectin is an FDA-approved medication in 2015.
• Ivermectin is an FDA-approved medication in 2015.
• The FDA already, it's a prescription-only drug.

Bills: S0036, S0620, S0796, S0934, S1080, S1096, S1366, S1536, S1548, S1580, S1588, S1620, S1756, S7034, S7044

Keywords: nursing title, advanced practice registered nurse, advertising, professional standards, disciplinary action, candidate qualifying, federal office, election integrity, regulatory compliance, political candidacy, veterinary medicine, telehealth, veterinary professional associate, animal health, public safety, access to veterinary services, payment bond exemption, Habitat for Humanity, Florida Forever Act, land acquisition

Summary: The committee first took up SB 354, the “Blue Ribbon Projects” bill, which creates a framework for large planned communities on at least 15,000 contiguous acres with 60% reserved area and a streamlined local review process. Senator McLean presented the bill and a strike-all amendment, and members raised concerns about local control, conservation enforceability, data centers, concurrency, multi-county projects, and whether reserve lands could later be converted. Audubon Florida and 1,000 Friends of Florida opposed the bill, arguing the conservation protections were not permanent enough and that the reserve areas could be changed later; small-county representatives also worried about tax-base impacts. Supporters argued the bill would better manage growth, preserve green space, and provide a more orderly alternative to sprawl. After debate, the committee voted to report the bill favorably. The committee then approved SB 620 on candidate qualifying, which requires candidates for federal, state, county, district, judiciary, school, and school board offices to disclose any non-U.S. citizenship. Amendments added disclosure about whether federal candidates intend to trade stock if elected and adjusted 2026 congressional qualifying procedures in the event of redistricting, including a new qualifying window and petition rules. The bill was reported favorably after brief support from a member of the public and discussion about candidate vetting. The committee also reported favorably CS/CS/CS/SB 1452, a Department of Financial Services bill with amendments addressing My Safe Florida Home notices, condo pilot eligibility, firefighter hiring, unclaimed property, and related financial-services provisions. Next, the committee approved CS/CS/SB 1620, a school board members’ bill of rights. A substitute amendment narrowed the bill to access to records, fiscal transparency, and nondisclosure agreements, while preserving board members’ rights to timely documents, budget information, and public comment, and setting deadlines for records requests. Superintendents and a school board member testified in support, saying the bill clarifies roles and prevents board members from being frozen out. The committee also passed CS/HB 245, which replaces the term “child pornography” with “child sexual abuse material”; one senator supported the terminology change but warned about preserving legal precedent and avoiding appellate issues. The committee then reported favorably SB 1548, an update to the Live Local affordable housing law expanding eligible sites and clarifying setbacks, airport proximity, and fair-housing protections. Finally, the committee took up the veterinary medicine bill creating veterinary professional associates. The bill allows trained master’s-level VPAs to perform limited veterinary services under a veterinarian’s supervision, and an amendment tightened the standard to immediate supervision on premises. Supporters said the measure would expand access to care, especially in rural areas with vet shortages, while opponents argued it added unnecessary regulation. After testimony from veterinary educators and others, the bill continued with support expressed by committee members, including praise for the direct-supervision amendment.

Transcript Highlights:

• Right now, many of these therapies fall into a gray area, not fully approved by the FDA for broad use
• And unfortunately, right now at the federal level, I do know firsthand from meeting with the FDA and
• And unfortunately, right now at the federal level, I do know firsthand from meeting with the FDA and
• has expired, and the FDA has not given any further regulatory guidelines.
• The drugs have to be FDA approved, right? That's the first safeguard.

Bills: SB1052, SB1115, SB1118, SB1120, SB1121, SB1124, SB1171, SB1172, SB1174, SB1175, SB1214, SB1233, SB1235, SB1316, SB1345, SB1372, SB1399, SB1458, SB1494, SB1496, SB1564, SB1602, SB1621, SB1628, SB1630, SB1631, SB1668, SB1672, SB1814, SB1821

Keywords: assisted living, health care, hyperbaric oxygen therapy, physician orders, informed consent, AHCCCS, remote work, state agency, employment, public health, housing, zoning, middle housing, urban development, duplexes, triplexes, fourplexes, townhomes, historic preservation, radiation protection

Summary: The committee first heard Senate Bill 1121, which would prohibit hospitals from requiring lead aprons for cardiac catheterization staff when a radiation protection system is in place, while still allowing hospitals to require aprons outside the designated safety zone or when exposure levels warrant additional protection. An amendment added flexibility for radiation safety officers to require lead or other PPE if exposures approach occupational limits and removed expedited rulemaking language. Supporters, including the sponsor and interventional cardiologists, argued the devices reduce radiation and orthopedic injuries and improve recruitment and retention; hospital groups shifted to neutral after the amendment. The committee adopted the amendment and passed SB 1121 on a 9-2 vote. The committee then considered Senate Bill 1120, which would require hospitals performing cardiac catheterization procedures to equip at least 50% of those rooms with radiation protection systems by 2027. Supporters said the systems protect clinicians from radiation and long-term injury, while opponents, including hospital and radiology groups, argued the bill was overly prescriptive, could create a captive market, and might not fit all rooms or procedures. After adopting a children’s hospital exemption amendment, the committee passed SB 1120 on a 6-6 vote, with the chair breaking the tie in favor of the bill. Senate Bill 1118, an appropriation measure tied to the radiation protection system proposal, was also advanced after brief discussion, passing 6-5. The committee then took up Senate Bill 1214, which would create guardrails for non-FDA-approved stem cell and regenerative therapies, including provider standards, informed consent, advertising limits, reporting requirements, and a private right of action for violations. Supporters described it as a patient-protection and access bill, while testimony emphasized concerns about unregulated “bad actors” and patients traveling out of state for treatment. The committee adopted an amendment removing a reference to the National Law and passed SB 1214 on a 9-3 vote. The transcript then began discussion of SB 1630, which would create a Medicaid-funded home and community-based service benefit for adults with serious mental illness, with AHCCCS taking a neutral position and estimating a significant fiscal impact.

Transcript Highlights:

• That seemed like something that would be done on the FDA sector or would be done on the FDA sector or
• And well, the FDA has has agreed to what was well, the FDA has has agreed to what was well, the FDA has
• But wouldn't the FDA group of of foods. But wouldn't the FDA group of of foods.
• Uh um I do not know about FDA. That's that's the not know about FDA.
• We have a FDA that's Representatives. We have a FDA that's Representatives.

Keywords: 1136, house, all

Transcript Highlights:

• of a primary care doctor who has any knowledge of the disease to only 5% of rare diseases having any FDA-approved
• 00:03:45.200> diseases<00:03:45.959> having<00:03:46.319> any<00:03:46.560> FDA
• <00:03:47.280> approved rare diseases having any FDA approved rare diseases having any FDA

Keywords: 919, house, all

Summary: The committee heard House File 1501, which would fund the Minnesota Rare Disease Advisory Council and make the current fiscal year 2025 budget its permanent base. Representative Murphy said the bill would provide about $342,000 in general fund money for the 2026-27 cycle and argued that the council helps shorten diagnosis times, support research, and keep Minnesota a leader in rare disease work. Erica Barnes, the council’s executive director, testified in support and explained that the council was established in 2022 to improve care for the estimated one in 10 Minnesotans living with a rare disease. She said the council needs the full $668,000 level it operated with this year to maintain its statutory duties, noting that the current ongoing base is about $326,000 and that the extra funding was previously one-time money. Barnes described the barriers faced by rare disease patients, including long diagnostic delays, limited provider knowledge, and the fact that only a small share of rare diseases have FDA-approved treatments. She said rare disease care is costly to the health system and that the council has used prior funding to convene the community more regularly and carry out its work. Representative Leing questioned why the budget should be doubled and asked what additional work the council would do with the higher amount; Barnes responded that without the larger ongoing appropriation the council would fall back to 1.8 FTE and would have to stop some programs. Representative Hingson Jger spoke in support, saying the council’s collaboration has been valuable for policy work in the genetic and rare disease space. In closing, Murphy emphasized Minnesota’s leadership in rare disease and shared a personal story about how diagnosis and treatment changed his family’s life. No public testimony was offered. The chair then laid House File 1501 over for possible inclusion in the omnibus bill.

Transcript Highlights:

• FDA-designated breakthrough therapies, including MDMA and psilocybin-assisted treatments, have shown
• FDA-designated breakthrough therapies, including MDMA and psilocybin-assisted treatments, have shown
• <00:42:56.000> designated<00:42:56.520> breakthrough<00:42:57.200> therapies FDA
• <00:44:25.359> as<00:44:25.520> breakthrough designated by the FDA as breakthrough
• designated by the FDA as breakthrough therapies<00:44:26.400> for<00:44:26.559> their<00

Keywords: 912, senate, all

Summary: The Health and Human Services Committee heard testimony on several measures related to child welfare, health care access, overdose response, disability services, and waste management. For SB 710 on child welfare, the Department of Human Services, the Office of Wellness and Resilience, the Attorney General’s office, and multiple advocacy groups testified in support, with the Governor’s office noting support but deferring to the Attorney General on implementation because of separation-of-powers concerns. For SB 952 on child welfare services, DHS, the Governor’s office, and child- and trauma-informed care advocates supported the bill, saying it would help families access services, provide basic material support, and reduce strain on the child welfare system. SB 954 on a home health services rate study also drew support, including from DHS, the Hawaii Healthcare Association, and a public testifier who said the study would help ensure funds reach low-income, disabled, and kupuna recipients. SB 957 on overdose prevention received support from the Department of Health and the Attorney General, who said overdose prevention centers are evidence-based but raised federal-law concerns and recommended amendments; the Hawaii Health and Harm Reduction Center and others also testified in support. The committee then moved to the 1:00 regular calendar and heard SB 850 on disability health disparity, which was supported by the Executive Office on Aging, the Hawaii State Council on Developmental Disabilities, the Hawaii Disability Rights Center, self-advocates, and others. Testimony emphasized that a disparity study could improve workforce development, training, and services for people with disabilities. SB 838 on continuous glucose monitoring drew support from health agencies and advocates, with testimony stressing that monitors can be critical for some diabetes patients. SB 829 on health care was supported by the Department of Health and health care stakeholders, who said it would help rotating physicians serve neighbor islands without local hospital privileges and align with CMS rules. SB 446 on waste management drew mixed testimony: the Department of Health and several public entities provided comments, the County of Maui opposed, and environmental advocates urged stronger aquifer protections and limits on ash reuse. During decision making, the committee adopted recommendations to pass SB 298, SB 322, SB 299, SB 450, SB 451, SB 949, SB 710, SB 957, SB 69, and SD 952 with various amendments, including technical changes, blank appropriations, and defective dates. SB 323, SB 324, SB 712, SB 950, SB 954, and SB 959 were deferred, largely because companion House measures were moving or similar Senate measures had already passed. The chair also announced recesses to find quorum and noted that some bills from the earlier Monday calendar were being deferred to avoid duplication.

Transcript Highlights:

• Beyond that, he said it is really technically an FDA issue, a food safety issue at FDA, and not initially
• But in his mind, this is a federal FDA issue. Representative Hansen, Mr.
• In his mind, this is a federal FDA issue.
• She said the department follows FDA guidance for its commercial feed and food division program, and that

Keywords: 1183, house

Transcript Highlights:

• are awaiting FDA approval, and they're still being sold.
• I want to reiterate what Linda mentioned: the FDA has not issued a complete ban on flavored products,
• So we're waiting for actions from the FDA.
• It's been talked about for a few years already, but FDA and all of these other entities, I think, are
• Secretary is that the FDA, of course, hasn't issued a ban on flavored products yet.